CD Genomics, a leading provider of genomic and epigenomic sequencing solutions, has introduced oxBS-seq, a game-changing technology for accurate whole-genome DNA methylation profiling.
DNA methylation, an essential epigenetic modification, plays a key role in numerous biological processes like gene expression regulation, genomic imprinting, and development. Disturbances to normal DNA methylation patterns can lead to diseases, like cancer. As such, accurate DNA methylation profiling has become profoundly important in biomedical research.
CD Genomics, renowned for its genomic and epigenomic solutions, stands at the forefront of this research with the introduction of oxBS-seq, a technology that offers single-base resolution, reducing the risk of false positives and negatives in DNA methylation detection.
Oxidative Bisulfite sequencing (oxBS-seq), combines oxidative conversion with bisulfite sequencing to differentiate between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). This revolutionary technology illuminates the epigenetic landscape with incomparable precision.
"Our OxBS-seq service utilizes advanced technologies, enabling a complete view of 5mC and 5hmC, both play critical roles in epigenetic regulation," said the Chief Scientist of CD Genomics. "This technique improves the accuracy of methylation data, advancing our understanding of disease mechanisms and potentially pointing the way to novel therapeutic approaches."
Apart from the introduction of oxBS-seq, CD Genomics offers a comprehensive suite of services for epigenomics research, including Reduced Representation Bisulfite Sequencing (RRBS), MeDIP-seq, ChIP-seq and more. Each service employs strict quality controls to ensure the validity of sequencing data, assisting researchers in making significant scientific breakthroughs.
Epigenomic variations have been linked to a range of health conditions, including neurodegenerative disorders, autoimmune diseases, and cancer. Furthermore, they can offer insights into developmental biology and the environmental factors affecting gene expression.
With state-of-the-art oxBS-seq technology, CD Genomics is poised to accelerate advances in epigenomic research. Its commitment to providing comprehensive solutions, including tailored study design and data analysis support, highlights CD Genomics’ ongoing investment in supporting the scientific community.
CD Genomics continue to pioneer, venturing beyond the genome into the dynamic world of the epigenome. The introduction of oxBS-seq exemplifies their commitment to delivering game-changing technologies that have the potential to redefine our understanding of the genetic and epigenetic underpinnings of disease.
About CD Genomics
CD Genomics stands as a premier provider of sequencing and bioinformatics services. With an unwavering dedication to quality, innovation, and customer satisfaction, CD Genomics serves researchers worldwide as they pursue groundbreaking discoveries.
Contact
Address: Shirley, NY 11967, USA
Email: contact@cd-genomics.com